Predict your next investment

Ilya Pharma company logo
HEALTHCARE | Drug Development
ilyapharma.se

See what CB Insights has to offer

Founded Year

2016

Stage

Option/Warrant | Alive

Total Raised

$7.61M

About Ilya Pharma

Ilya Pharma develops drug candidates for PoC in clinical phase I and II from its technology platform of lactic acid bacteria expressing different human therapeutic proteins.

Ilya Pharma Headquarter Location

S:t Goransgatan 23

Uppsala, 753 26,

Sweden

+46 (0)706366494

Latest Ilya Pharma News

Ilya Pharma to initiate Phase II trial

Jun 28, 2021

Ilya Pharma to initiate Phase II trial Search for content, post, videos The company has received approval from the Swedish Medical Product Agency and Swedish Ethical Review Authority to initiate a Phase II clinical study of its ILP100 gene therapy for the treatment of difficult diabetic wounds. ILP100h has recently been assigned the INN name emilimogene sigulactibac by the WHO and represents a new-in-class drug candidate, engineering Limosilactobacillus reuteri bacteria to produce and release the key human chemokine CXCL12 at the actual wound site, describes the company in a press release. After delivery, ILP100 enhances the healing properties of immune cells in the wound. Phase I results released earlier this year indicate that ILP100-treated wounds in healthy subjects healed on average 6 days and, for the highest dose, 11 days faster than controls. “With the phase II clinical trial, we will for the first time study the biologic effect of ILP100 in difficult wounds in patients one of the intended patient groups for future commercial use of ILP100 where today’s standard of care is not sufficient. We have designed this 26-week trial to both allow assessment of the clinical outcomes mentioned as the most important by patients and regulatory authorities, including detailed wound analyses with AI-augmented imaging technology as well as non-invasive imaging of blood perfusion, and at the same time further characterize ILP100 in a clinical setting,” says Andreas Fasth, Ilya Pharma’s Head of Clinical Developments. “A true milestone” “This is a true milestone in both the clinical development of ILP100 and proof of the concept of using local delivery of biologics by the ILP-technology platform as we move to Phase II,” says Evelina Vågesjö, Ilya Pharma’s CEO. “We now look forward to showing biological effects on wound healing and important long term clinical outcomes in patients with diabetes and difficult non-healing wounds. Here ILP100 has the potential to prove superior to the only other two pharmaceuticals approved as we already have much better positioning and PoC data. In addition, we will proceed with the planned clinical development in treatment of postsurgical wounds in obesity, diabetes and prediabetes, as well as pre-clinical- development and clinical positioning for ulcers of the GI tract.”

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Ilya Pharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Ilya Pharma is included in 1 Expert Collection, including Biopharmaceuticals.

B

Biopharmaceuticals

5,882 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Ilya Pharma Patents

Ilya Pharma has filed 2 patents.

The 3 most popular patent topics include:

  • Biotechnology
  • Cytokines
  • Interleukins
patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/23/2015

6/30/2020

Cytokines, Clusters of differentiation, Transcription factors, Immune system, Molecular biology

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

12/23/2015

00/00/0000

Grant Date

6/30/2020

00/00/0000

Title

Subscribe to see more

Related Topics

Cytokines, Clusters of differentiation, Transcription factors, Immune system, Molecular biology

Subscribe to see more

Status

Grant

Subscribe to see more

Ilya Pharma Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Ilya Pharma Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.